Clinical trials: Attention-Deficit Hyperactivity Disorder(ADHD)
- Condition Attention-Deficit Hyperactivity Disorder(ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
The purpose of this study is to determine whether SPD465 is safe and effective in the treatment of ADHD in young adult drivers after a duration of 16 hours.
- Trial name
- NCT00458445
- Testing
- SPD465
- Where
- United States
- Sponsor
- Shire
ADHD
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
The purpose of this research study is to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of twice daily oral doses of V81444 in adults with ADHD.
- Trial name
- NCT02253745
- Testing
- V81444
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vernalis (R&D) Ltd
ADHD, Sleep Disturbance
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant…
- Conditions
- ADHD, Sleep Disturbance, Brain Fog
- Trial name
- NCT07380412
- Testing
- Stasis Daytime and Nighttime
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Outliers, Inc.
Attention-Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder…
- Trial name
- NCT05257265
- Testing
- Centanafadine Hydrochloride
- Where
- United States
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
- Trial name
- NCT00466791
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Noven Therapeutics
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552902
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 95 sites in United States, Canada and 3 more
- Volunteers
- 549 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to provide data on the effectiveness of the OROS Methylphenidate Hydrochloride (HCl) formulation compared to placebo and standard immediate-release Ritalin with respect to improving attention and…
- Trial name
- NCT00269776
- Testing
- OROS (methylphenidate HCl), Ritalin (methylphenidate)
- Sponsor
- Alza Corporation, DE, USA
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD).
- Trial name
- NCT00192023
- Testing
- atomoxetine 0.5 mg/kg/day, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day
- Where
- 12 sites in Italy
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects
This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD.
- Trial name
- NCT00995085
- Testing
- Extended Release Metadoxine
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Alcobra Ltd.
Adult Attention-deficit/Hyperactivity Disorder
Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder
Non-interventional study to gain further information about the therapy progression in routine treatment of adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- IDEA (NCT01615679)
- Where
- Germany
- Volunteers
- 468 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
ADHD
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
- Trial name
- NCT02168127
- Testing
- Drug: PRC-063, PRC-063
- Where
- 35 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty…
- Trial name
- ADD201 (NCT00983814)
- Testing
- Droxidopa+Carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Chelsea Therapeutics
Attention Deficit Disorder With Hyperactivity
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
- Trial name
- NCT00174226
- Testing
- Atomoxetine, Buspirone
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Pfizer
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD
- Trial name
- NCT03247556
- Testing
- 400mg SPN-812, 600mg SPN-812
- Where
- 14 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).
- Trial name
- NCT00191386
- Testing
- Atomoxetine hydrochloride
- Where
- 24 sites in Japan
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Phenylketonuria
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
- Trial name
- NCT01114737
- Testing
- Sapropterin dihydrochloride
- Where
- 36 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- BioMarin Pharmaceutical
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD.
- Trial name
- NCT05428033
- Testing
- centanafadine capsule
- Where
- United States
- Volunteers
- 574 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-deficit Hyperactivity Disorder
A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
The purpose of this observational study is to explore the efficacy of methylphenidate hydrochloride in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-scheduled for affective…
- Trial name
- NCT01624649
- Testing
- Methylphenidate hydrochloride, Atomoxetine
- Where
- 9 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea